This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Form D industry group

Pharmaceuticals

Rounds

1

Latest round

Form D equity offering 2024-03-21

Latest round amount

$171M

Investors

0

People

5

Incorporated

2023

Revenue range

Decline to Discloseas stated on Form D

• Occurred

  May 6, 2024
  Form D filed

  Endo, Inc. filed Form D/A: $170,574,224 sold of $170,574,224, Pharmaceuticals

  Form Dobserved 8 days ago
  $171M

Also named here, with no published line of their own (reach them through the firm): Patrick Barry (Executive Vice President; President, Global Commercial Operations), Blaise Coleman (President; Chief Executive Officer), Matthew Maletta (Executive Vice President; Chief Legal Officer; Secretary), Frank Raciti (Vice President; Controller; Chief Accounting Officer), Mark Bradley (Executive Vice President; Chief Financial Officer), Scott Hirsch (Director), Paul Efron (Director), Paul Herendeen (Director), Marc Yoskowitz (Director), Sophia Langlois (Director), Andy Pasternak (Director).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Graph

Venture Capital

Canonical id

dfx:vc:e358ac65-dc87-42d4-b842-f8a2f360876d

First observed

Sep 12, 2026

Last observed

Sep 12, 2026 8 days ago

Resolution

Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.